Let's Talk Recovery (LKRV) Up 40%. Today announced its New Business Plan which is highlighted below. Among some of the more interesting observations are that the Company sees a profit beginning in the 3Q of '07 and continuing through the 2nd quarter of '08. A link to the entire report is below.

Benda Pharmaceutical (BPMA) after our alert last night, went from $2.20 to $2.35, on over 14x average volume. If you choose do a quick search on Google for Gendicine you will see several independent references referring to it as the real deal. Certainly a Company worth tracking.

Benda Pharmaceutical (BPMA)

Copyright SmallCapReview. All rights reserved. SCR is not a Registered Broker/Dealer or Financial Advisor, nor do we hold ourselves out to be. All materials presented on our web site and individual reports released to the public through this web site, e-mail or any other means of transmission are not to be regarded as investment advice and are only for informative purposes. Before making a purchase or sale of any securities featured on our web site or mentioned in our reports, we strongly encourage and recommend consultation with a registered securities representative. This is not to be construed as a solicitation or recommendation to buy or sell securities. As with any stock, companies we select to profile involve a degree of investment risk and volatility. Particularly Small-Caps and Penny Stocks. All investors are cautioned that they may lose all or a portion of their investment if they decide to make a purchase in any of our profiled companies. Past performance of our profiled stocks is not indicative of future results. The accuracy or completeness of the information on our web site or within our reports is only as reliable as the sources they were obtained from. The profile and opinions expressed herein are expressed as of the date the profile is posted on site and are subject to change without notice. No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. SCR may hold positions in securities mentioned herein, and may make purchases or sales in such securities featured on our web site or within our reports. In order to be in full compliance with the Securities Act of 1933, Section 17(b), SCR will disclose in it's disclaimer, what, if any compensation was received for our efforts in researching, presenting and disseminating this information to our subscriber database and featuring the report on the SCR web site. SCR has been compensated eight thousand five hundred dollars by Let's Talk Recovery and two thousand dollars by a third party (APS) for its efforts in presenting the BPMA and LKRV profiles on its website and distributing it to its database of subscribers. SCR has not been compensated by any other company mentioned. SCR may decide to purchase or sell shares on a voluntary basis in the open market before, during or after the profiling period of this report.

The Reader should verify all claims and do their own due diligence before investing in any securities mentioned. Investing in small-cap securities is speculative and carries a high degree of risk.

We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (SEC) at: http://www.sec.gov and/or the National Association of Securities Dealers (NASD) at: http://www.nasd.com.